Details:
BRT-DA01 (bemdaneprocel), is an investigational therapy comprised of dopamine producing neurons derived from pluripotent stem cells, is surgically implanted into the brain of a person with Parkinson’s disease.
Lead Product(s): Bemdaneprocel
Therapeutic Area: Neurology Product Name: BRT-DA01
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: BlueRock Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
KUR-101 is an atypical opioid receptor modulator with a unique pharmacology that may make it safer for chronic use. Its deuteration improves its pharmacokinetic and overall safety profile while reducing dosing requirements.
Lead Product(s): KUR-101
Therapeutic Area: Neurology Product Name: KUR-101
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2022
Details:
The short-term Phase 1b study with PD patients will be conducted by Quotient Sciences in e clinical trial initiation of a first-in-patient Phase 1b study for anle138b in patients with mild to moderate Parkinson´s Disease (PD).
Lead Product(s): Anle138b
Therapeutic Area: Neurology Product Name: Anle138b
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2020
Details:
The Phase I trial aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of an investigational peripherally restricted Nociceptin/orphanin peptide receptor (NOP) agonist following single and multiple-ascending doses.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2020
Details:
Anle138b which was administered in doses of up to 300 mg daily, demonstrated excellent safety and tolerability profiles at all dose levels and reached significantly higher plasma levels in humans than those required for full therapeutic efficacy in animal models.
Lead Product(s): Anle138b
Therapeutic Area: Neurology Product Name: Anle138b
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: The Michael J. Fox Foundation for Parkinson's Research.
Deal Size: $1.4 million Upfront Cash: Undisclosed
Deal Type: Funding August 05, 2020